RxDoctor Payments Data

Jason Wertheimer, DO

Family Medicine · San Francisco, CANPI 1154855922

Payments from drug & device makers

$2,005in general payments, 2019–2025

Across 100 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$415
  • Otsuka America Pharmaceutical, Inc.$304
  • Amgen$181
  • E.r. Squibb & Sons, L.L.C.$158
  • Lilly USA, LLC$157
  • AstraZeneca$133
  • plus $656 from 13 others

What the payments were for

  • Food & beverage$2,000100%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,005 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$6,037
Medicare patients
31
Services billed
57

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala14$52,425
JardianceEmpagliflozin29$31,114
EliquisApixaban16$20,081
OzempicSemaglutide11$19,262
JanuviaSitagliptin Phosphate18$16,525
XareltoRivaroxaban14$16,204
GemtesaVibegron14$9,547
Combivent RespimatIpratropium/Albuterol Sulfate11$9,494
Atorvastatin Calcium177$1,997
Amlodipine Besylate162$1,319
Valsartan11$892
Metoprolol Succinate46$806
Gabapentin37$700
Irbesartan16$678
Tamsulosin Hcl39$660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$37$52,42514 claims
Boehringer IngelheimJardiance, Combivent Respimat$16$40,60840 claims
PfizerEliquis$52$20,08116 claims
Novo NordiskOzempic$415$19,26211 claims
MerckJanuvia$58$16,52518 claims
Sumitomo Pharma America, Inc.Gemtesa$101$9,54714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →